Third, although triple immunotherapy comprising an anti-PD-1 mAb, STING agonist, and anti-LAG-3 mAb demonstrated adequate biosafety in murine HCC models, further investigations are warranted to evaluate its efficacy, potential toxicities, and optimal dosage in human subjects. This evidence concerns the gene LAG3 and hepatocellular carcinoma.